La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Senti Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Senti Biosciences..

Senti Biosciences (NASDAQ:SNTI) Azioni, Catena delle Opzioni

SENTI BIOSCIENCES INC

Senti Biosciences

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Senti Biosciences Inc

<h3>Gainers</h3>
<ul>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock increased by 180.5% to $7.91 during Wednesday's pre-market session. The company's market cap stands at $5.3 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 51.95% to $1.21. The market value of their outstanding shares is at $3.4 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 36.12% to $6.82. The company's market cap stands at $6.9 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares increased by 23.48% to $0.38. The market value of their outstanding shares is at $1.2 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock increased by 21.94% to $3.39. The company's market cap stands at $88.4 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares rose 17.82% to $1.06. The market value of their outstanding shares is at $16.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock declined by 26.8% to $14.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.9 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) stock fell 22.02% to $0.64. The market value of their outstanding shares is at $15.0 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock declined by 19.65% to $0.23. The market value of their outstanding shares is at $20.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 15.07% to $5.92. The market value of their outstanding shares is at $17.0 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 13.11% to $1.26. The company's market cap stands at $90.1 million. </li>
<li>Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) shares declined by 10.78% to $11.84. The company's market cap stands at $230.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACXP

APVO

BDRX

CBIO

CERO

CTOR

EYEN

GOVX

HSDT

SNTI

STSS

XAIR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML. Additionally, the Company released a Virtual Investor "What This Means" segment to discuss the Orphan Drug Designation for SENTI-202, now available <a href="https://www.globenewswire.com/Tracker?data=tn5ZUbAFVUbl4XewuzL0h6Q-yGIUQJzSRWva7T8CQM5zyfMVWW77PH15J3Eq0uZnC7U78xpnzFWiaG9edbRb0_BRsFMe01aeYVyyGoFVQ3o=">here</a>.
Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences commented, "SENTI-202 continues to demonstrate encouraging promise as a potential treatment option for relapsed/refractory AML, an indication with significant unmet need and a dismal median survival rate of 5.3 months3. Receiving Orphan Drug Designation for SENTI-202 provides further validation to our novel approach to overcoming AML heterogeneity and protecting healthy cells, and underscores the need for new and effective treatment options. Building upon our recently reported positive preliminary results, this important milestone bolsters our commitment to advancing the development of this important program forward."
SENTI-202 is the Company's first-in-class off-the-shelf Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while sparing healthy bone marrow cells. SENTI-202 is currently being evaluated in a Phase 1 clinical trial (<a href="https://www.globenewswire.com/Tracker?data=N3fZNulJE3fUGlo0eyD0zQm8v9etIVbYPdNBtDc7DC7IljNtHBjhnys3F_22LRmftXTbYqYIjlC8d9_Bsh12iKCdc1mZKzvZe59vKWUxURm00OBnzLeS3cLC3VbovVWT">NCT06325748</a>).
The FDA Office of Orphan Products Development grants Orphan Drug Designation to products that show the potential to treat rare diseases or conditions, which primarily are those that affect fewer than 200,000 people in the U.S. Orphan Drug Designation qualifies a company for a number of benefits intended to provide incentives to develop drugs for rare diseases or conditions, including tax credits, exemptions from certain FDA fees for clinical trials and the potential for seven years of market exclusivity following drug approval.

Government

News

Regulations

Senti Bio's Experimental Cancer Treatment Gets FDA Boost for Targeting Deadly Leukemia

<a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1078725" title="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1078725">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1078725</a>

Biotech

General

Senti Biosciences gets FDA Orphan Drug Designation For SENTI-202 For Treatment Of Acute Myeloid Leukemia

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) with a Buy and maintains $12 price target.

Price Target

Analyst Ratings

Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

Laidlaw &amp; Co. analyst Yale Jen initiates coverage on Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) with a Buy rating and announces Price Target of $15.

Initiation

Laidlaw & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $15

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock rose 41.5% to $2.15 during Thursday's after-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares moved upwards by 30.86% to $0.26. The company's market cap stands at $16.7 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 28.97% to $4.05. The company's market cap stands at $11.6 million. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) shares moved upwards by 8.47% to $15.1. The company's market cap stands at $1.2 billion. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares increased by 7.27% to $0.57. The company's market cap stands at $19.0 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) stock rose 6.86% to $1.09. The company's market cap stands at $144.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares declined by 18.7% to $20.0 during Thursday's after-market session. The company's market cap stands at $534.2 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 10.12% to $3.2. The market value of their outstanding shares is at $83.4 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares decreased by 9.44% to $8.06. The market value of their outstanding shares is at $116.8 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock fell 8.15% to $3.86. The company's market cap stands at $58.7 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares decreased by 7.83% to $2.12. The market value of their outstanding shares is at $1.5 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares declined by 7.7% to $3.0. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

GLYC

LIMN

NIVF

PTHL

RANI

RAPT

SCNI

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares moved upwards by 91.2% to $24.3 during Thursday's pre-market session. The company's market cap stands at $649.1 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) shares rose 26.65% to $0.85. The company's market cap stands at $52.1 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares increased by 23.69% to $0.71. The company's market cap stands at $5.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock rose 22.2% to $770.0. The market value of their outstanding shares is at $10.0 billion. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock rose 16.84% to $6.45. The company's market cap stands at $2.7 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) shares increased by 12.98% to $0.65. The company's market cap stands at $58.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares fell 76.7% to $0.76 during Thursday's pre-market session. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock fell 37.29% to $1.48. The company's market cap stands at $48.3 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares declined by 11.8% to $0.46. The company's market cap stands at $7.7 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares fell 11.51% to $3.0. The market value of their outstanding shares is at $78.2 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares fell 9.1% to $0.3. The market value of their outstanding shares is at $11.7 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares fell 8.98% to $0.28. The market value of their outstanding shares is at $17.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

ATHA

CBUS

CGTX

CNTX

KAPA

KRON

SILO

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares increased by 237.2% to $2.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $128.5 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock moved upwards by 18.44% to $0.28. The company's market cap stands at $13.9 million. </li>
<li>Veru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) shares rose 15.91% to $0.59. The market value of their outstanding shares is at $86.4 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 12.77% to $2.56. The market value of their outstanding shares is at $2.4 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) stock increased by 9.37% to $12.25. The company's market cap stands at $536.5 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 8.66% to $1.38. The company's market cap stands at $149.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock decreased by 30.4% to $1.58 during Wednesday's pre-market session. The company's market cap stands at $27.7 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock fell 16.47% to $0.99. The market value of their outstanding shares is at $3.1 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 13.95% to $0.59. The market value of their outstanding shares is at $2.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock fell 11.75% to $2.33. The market value of their outstanding shares is at $1.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 10.86% to $447.17. The market value of their outstanding shares is at $5.8 billion. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock decreased by 7.86% to $3.05. The company's market cap stands at $79.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

ASBP

IMNN

MAZE

REVB

SONN

SPRO

VERU

WORX

<h3>Gainers</h3>
<ul>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock moved upwards by 10.9% to $0.67 during Tuesday's after-market session. The company's market cap stands at $7.6 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares increased by 7.01% to $3.05. The company's market cap stands at $9.4 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 5.62% to $4.88. The market value of their outstanding shares is at $74.2 million. </li>
<li>Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) shares rose 5.56% to $13.46. The company's market cap stands at $126.3 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares increased by 5.0% to $0.2. The company's market cap stands at $8.3 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) stock moved upwards by 5.0% to $0.84. The company's market cap stands at $47.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock declined by 17.2% to $1.88 during Tuesday's after-market session. The market value of their outstanding shares is at $32.9 million. </li>
<li>PharmaCyte Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMCB#NASDAQ">PMCB</a>) shares declined by 12.85% to $0.95. The market value of their outstanding shares is at $6.5 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 8.68% to $0.62. The market value of their outstanding shares is at $2.2 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) shares declined by 7.21% to $2.32. The company's market cap stands at $166.7 million. </li>
<li>Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) stock fell 7.11% to $3.79. The market value of their outstanding shares is at $119.3 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 6.79% to $3.05. The company's market cap stands at $79.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

BTMD

CARM

KRRO

LUCY

PMCB

PRLD

WGRX

12 Health Care Stocks Moving In Tuesday's After-Market Session

Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported the receipt of an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) upon the achievement of clinical study enrollment milestones. As previously announced, the CIRM awarded an $8 million grant to Senti Bio to support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML). To date, the Company has received a total of $7.4 million of the $8.0 million available under the grant.
"We are grateful for the continued support of the CIRM as we continue to rapidly enroll into our SENTI-202 clinical trial. We are committed to advancing this important program forward and based on the recently presented positive preliminary results, we are becoming more confident in its potential to provide a much-needed treatment option for patients," commented Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences.
SENTI-202 is the Company's first-in-class off-the-shelf Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while sparing healthy bone marrow cells. SENTI-202 is currently being evaluated in a Phase 1 clinical trial (<a href="https://www.globenewswire.com/Tracker?data=aPpS9xrrMSZ7chxX_Ly1ff2-y2KdHoV8I7ArdkJax4nptjmDCLWn9TewWi5OczwDmK7uIU8iTzWxLAN4XaVe9daDlj_9-749taK6S3LW0fACcKWVOuAwShJee6OqE5-y">NCT06325748</a>).
Positive preliminary results from the ongoing Phase 1 trial as well as correlative data from patients and preclinical data supporting Logic Gate mechanism of action were recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data showed that SENTI-202 was well-tolerated in the patients whose data was presented with no dose limiting toxicities and a maximum tolerated dose was not reached. The preliminary recommended Phase 2 dose (RP2D) was identified based on the totality of clinical data, including efficacy, as 1.5 x 109 CAR NK cells administered on Days 0,7,14 in 28-day Cycles following lymphodepleting chemotherapy. Two of three patients in the preliminary RP2D cohort achieved a composite Complete Remission (cCR); 5 of the 7 best overall response evaluable patients across all dose levels achieved an ORR (cCR + morphologic leukemia-free state) outcome and 4 of the 7 achieved cCR (3 CR with full hematologic recovery, and 1 CRh (CR with partial hematologic recovery)). Four of four cCR patients were MRD- (Measurable Residual Disease Negative) as assessed by local standard of care, with longest cCR duration of 8+ months ongoing.

Senti Bio Announces It Has Received Additional $1M Tranche From California Institute For Regenerative Medicines Grant For Advancing Clinical Development Of SENTI-202

Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announces the release of its new animated video for its lead asset in development, SENTI-202. The video can be accessed <a href="https://www.globenewswire.com/Tracker?data=gVe6n_hezL9R5psULOBI_IS4PgRcwxPlkrgBGIWncO9BFeGWimTNbP-_Iq2mHG9YEbnK4oxIDxjmtCe8ObbBi7xCyOmvAWEEES4avaLysIkdlZZSHA7LYUpgwVxmRnLE">here</a>.
SENTI-202 is the Company's First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while sparing healthy bone marrow cells. SENTI-202 has three main components:
<ul>
<li>OR Logic Gate "Kills" leukemia blasts and LSCs via CD33 OR FLT3 activating CAR (aCAR)​
<ul>
<li>CD33 and/or FLT3 expressed in ~95% of AML patients with CD33 being predominantly expressed on bulk blasts and FLT3 on LSCs​</li>
</ul>
</li>
<li>NOT Logic Gate "Protects" healthy HSC/HSPCs from ‘off-tumor, on-target' effects​
<ul>
<li>Protection of HSC/HSPCs via Endomucin (EMCN) inhibitory CAR (iCAR), even when they express CD33 and/or FLT3​</li>
<li>EMCN found predominantly on healthy HSC/HSPC surface, rarely on AML blasts ​</li>
</ul>
</li>
<li>Calibrated release IL-15 "Enhances" SENTI-202 and host immune cell activity and persistence</li>
</ul>
Senti Bio is currently enrolling adult patients with relapsed/refractory (R/R) CD33 and/or FLT3-expressing heme malignancies in a Phase 1 clinical trial for SENTI-202, which can be a potential first-in-class allogeneic off-the-shelf treatment for AML/MDS patients (<a href="https://www.globenewswire.com/Tracker?data=OtB0Gtt50YAnjQXlZLqYDT5fqmTs3pVzo4WapAeu0uoAyVdmw2TXbpOayU55YQ3MKy3c4TyOtFiPNxEObpAMUL_bNaJP6_Oiz7XJVeityp9I-0qNMKlZ1Px9cIFibbyZ">NCT06325748</a>).
<a href="https://www.globenewswire.com/Tracker?data=hCBb_YocTyqz81OEMGvkfALna9WUDOOCG7g_yh-hyHd9OIcmjKeHtGLSS9Se2uIq_RlyJzHws0YxqxPM28ZAAHD2RKnRo59nMLQgzfYjpLs_WRPTC7zFHkSPwlB8dLBi4c14ixfxR1S-ttjSKPsK5Xkt3sWhynA4xXUw6TgcOsY6R7aJVpnv6IdCk04Utz68IpthXxCSG14Azj6KlUokxn5NhqU-rwWTIg7cSbm_hQeiJLuOyd7CihNEVNIkYHcb">Positive preliminary results</a> from the ongoing Phase 1 trial as well as <a href="https://www.globenewswire.com/Tracker?data=2VcGZXxM1deg3y2tU2z_CXAGUUy0RXEEJcCv5mtlpc2w00tvb3jAa6Lh75F9TrHPDT6uWbUUPTjAFkKPr-5h8m91lg8uiSHXprqYSTvqkYXJ2FyFBDt48m3mWKRj0cCZL2i76LfrdGxyRFC_mA1OBDXPsf3A7dsPIS5D6EmBvvoW3F1INyZ_Sy4bX2cgEooYiwHyui9zPYkJvmpdi3tdvw==">correlative data</a> from patients and <a href="https://www.globenewswire.com/Tracker?data=fNQvpoJLX7Zk1AqMX4BjuRR7t2n7yvAbgOGMjzE2st0psDLAV2zYvEmIFUmHPKf8STTSORC0TRFS-m1i1R-WcWz13D_hJe0L5d7Df7bwv4m3rNd3z9gX7whBiHn86JlfTxKh9weJ1JC4nKiEtI7VpAebRJRpFsnnULTszoW2hZthWwltkCMDX5iSsr7Zjmhz">preclinical data</a> supporting Logic Gate mechanism of action were recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The presented data demonstrated SENTI-202 was well-tolerated with no dose limiting toxicities and a maximum tolerated dose was not reached. The preliminary recommended Phase 2 dose (RP2D) was identified based on the totality of clinical data, including efficacy, as 1.5 x 109 CAR NK cells administered on Days 0,7,14 in 28-day Cycles following lymphodepleting chemotherapy. 2 of 3 patients in the preliminary RP2D cohort achieved a composite Complete Remission (cCR); 5 of the 7 best overall response evaluable patients achieved an ORR (cCR + morphologic leukemia-free state) outcome and 4 of the 7 achieved cCR (3 CR with full hematologic recovery, and 1 CRh (CR with partial hematologic recovery)). 4 of 4 cCR patients were MRD- (Measurable Residual Disease Negative) as assessed by local standard of care. All cCR patients continue in remission with follow-ups ranging from 4+ to 8+ months ongoing.

Senti Biosciences Announces Release Of Its New Animated Video For Its Lead Asset In Development Senti-202 Cell Therapy Product Candidate Designed To Selectively Target And Eliminate CD33 And/Or FLT3-Expressing Hematologic Malignancies

Earnings

Senti Biosciences Q1 EPS $(1.41) Up From $(2.60) YoY

<h3>Gainers</h3>
<ul>
<li>Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) shares increased by 21.7% to $1.74 during Monday's after-market session. The market value of their outstanding shares is at $63.8 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares rose 17.73% to $1.66. The market value of their outstanding shares is at $22.8 million. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) shares moved upwards by 14.45% to $16.31. The market value of their outstanding shares is at $693.6 million. As per the news, the Q1 earnings report came out today. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares rose 11.79% to $122.7. The market value of their outstanding shares is at $12.2 billion. The company's, Q1 earnings came out today. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock increased by 11.76% to $0.19. The market value of their outstanding shares is at $4.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock increased by 11.27% to $0.21. The market value of their outstanding shares is at $5.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 22.2% to $0.86 during Monday's after-market session. The company's market cap stands at $5.1 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock declined by 15.0% to $11.85. The company's market cap stands at $280.4 million. As per the press release, Q1 earnings came out today. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock fell 9.24% to $0.85. The market value of their outstanding shares is at $60.7 million. </li>
<li>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) stock decreased by 8.13% to $30.54. The market value of their outstanding shares is at $932.2 million. As per the news, the Q1 earnings report came out today. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 8.12% to $3.01. The market value of their outstanding shares is at $78.3 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock declined by 8.05% to $67.99. The company's market cap stands at $7.2 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CORT

GCTK

HSTM

NBIX

NCNA

OGEN

SIBN

SXTC

TCMD

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares moved upwards by 67.4% to $0.02 during Tuesday's pre-market session. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares increased by 39.22% to $39.65. The company's market cap stands at $8.8 billion. </li>
<li>LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) stock rose 19.83% to $7.31. The company's market cap stands at $325.9 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock increased by 15.71% to $0.07. The market value of their outstanding shares is at $1.6 million. </li>
<li>Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) stock increased by 15.61% to $11.7. The company's market cap stands at $250.1 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 14.14% to $1.07. The market value of their outstanding shares is at $187.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares decreased by 20.7% to $1.0 during Tuesday's pre-market session. The company's market cap stands at $34.5 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 14.51% to $0.31. The company's market cap stands at $10.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 14.06% to $0.25. The market value of their outstanding shares is at $3.4 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock fell 13.45% to $5.15. The company's market cap stands at $78.4 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock declined by 11.32% to $0.86. The company's market cap stands at $137.7 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 9.16% to $3.31. The market value of their outstanding shares is at $85.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AARD

CYCC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRWD

ITRM

LFMD

LGMK

PTPI

RLMD

TVGN

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 34.5% to $0.01 during Monday's regular session. </li>
<li>CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) shares moved upwards by 32.81% to $29.71. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) stock rose 32.18% to $13.8. The company's market cap stands at $654.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares moved upwards by 30.56% to $1.2. The company's market cap stands at $11.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 24.21% to $2.36. The company's market cap stands at $22.2 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares moved upwards by 24.0% to $1.21. The company's market cap stands at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares fell 26.2% to $0.1 during Monday's regular session. The company's market cap stands at $3.9 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock fell 22.6% to $0.89. The company's market cap stands at $3.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 20.8% to $3.96. The market value of their outstanding shares is at $102.9 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock fell 18.94% to $0.26. The market value of their outstanding shares is at $13.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 18.74% to $0.15. The company's market cap stands at $6.7 million. </li>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock declined by 18.52% to $3.52. The company's market cap stands at $129.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

CGON

GELS

HCTI

IBIO

SPRB

TARA

ZYBT

12 Health Care Stocks Moving In Monday's Intraday Session

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified5 of 7 best
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified
5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort
4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care
Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data cut and longest durability of 8+ months
Company to host webcast to discuss the new Phase 1 SENTI-202 data today, April 28th at 8:30 AM ET; <a href="https://www.globenewswire.com/Tracker?data=AbxbR4ScrJ0izIo4Ac5VlxUHBOddH6gJTQ2V2yuu38djGt54HInP6iB0FrHdAu9eXGkLs1e8BNnHuvPkTAM4eOUtRU2gn8tsGBJHwLH2M9IHHXKIVb64CkWt6SNdqkU3YpZRIiFL8WAtnhDFJCBK_Q==">Register Here</a>
Announces certain preliminary first quarter 2025 financial results and provides pipeline update
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported additional positive preliminary data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for the treatment of relapsed/refractory (R/R) hematologic malignancies including acute myeloid leukemia ("AML"). As previously announced, the Company will host a <a href="https://www.globenewswire.com/Tracker?data=qnw9Be6du1Qo9doPNbJ7zdSPx5_1n2-DBTj98Jvxm8KeXiH6VyCDkvCbYRzXMVdCFNOvd1qv77SNVc4uIGAQqbLYB9d08aZoFAghd0w6_xgQbaly1JA0Tig5i-FyAJbfcSHd68iJmdd6ogneh-V6gUyBY3KKv7SStlNlv0XiHZo=">conference call and webcast</a> to discuss the presented data today, April 28, 2025, at 8:30 AM ET (details below).

Senti Biosciences Reports Additional Preliminary Data From Phase 1 Clinical Trial Of SENTI-202 For R/R Hematologic Malignancies Including AML

<h3>Gainers</h3>
<ul>
<li>Azitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock rose 35.0% to $0.41 during Thursday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) shares moved upwards by 9.11% to $1.28. The company's market cap stands at $126.5 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock rose 8.33% to $0.52. The market value of their outstanding shares is at $72.4 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares rose 7.63% to $1.55. The market value of their outstanding shares is at $6.7 million. </li>
<li>Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) shares rose 6.75% to $318.4. The market value of their outstanding shares is at $12.3 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) shares increased by 6.59% to $0.36. The market value of their outstanding shares is at $25.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares declined by 8.3% to $2.0 during Thursday's after-market session. The market value of their outstanding shares is at $3.4 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares decreased by 7.59% to $0.29. The company's market cap stands at $23.1 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 7.04% to $0.22. The company's market cap stands at $1.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 6.52% to $4.59. The market value of their outstanding shares is at $119.3 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 5.96% to $0.98. The market value of their outstanding shares is at $2.8 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock declined by 5.92% to $0.46. The market value of their outstanding shares is at $45.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALEC

AZTR

CNSP

MNDR

OVID

PCSA

SNES

VNRX

XTNT

SOUTH SAN FRANCISCO, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that three abstracts have been selected for an oral minisymposium and poster presentations at the <a href="https://www.globenewswire.com/Tracker?data=0d6FDDS7V7yE7A3brrle3XLDGZUiCYJJR3VHPVQvSTC8-Tkf3B6VQ5MmccHOA03HYqiDC8IO_QazUzAq7KjzuoLYNQ0W2AePXDs3ByBHsva-Gi2fZ87GUH5R-C9-BwyQ7s_ZgjSg4UKMRxvpoJfsCR1MNvhe34k_dMTHTGq5_pd7TPE0QV8L2W-pEwBeUk6L4Vgi3-OGcbW5ZjTmVIDhZA==">American Association for Cancer Research (AACR) Annual Meeting 2025</a>, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL.
Kanya Rajangam, MD, PhD, President, Head of R&amp;D and Chief Medical Officer of Senti Bio commented, "We are excited to present updated clinical and correlative data from our ongoing SENTI-202 trial, along with detailed preclinical characterization of our Logic Gate technology. The preclinical data shows the EMCN inhibitory CAR (our NOT gate) protects healthy bone marrow cells from on-target off-tumor toxicity in vivo. Taken together, this data continues to support our enthusiasm for the potential of SENTI-202 to treat r/r AML and for Logic Gating, including our unique NOT gates, to be broadly applied to oncology to enhance the selective targeting of cancer while sparing healthy cells that may express the same targets."

Senti Bio To Release SENTI-202 Clinical Data And Novel Logic Gated Gene Circuit Mechanism Of Action In Oral And Poster Presentations At The American Association For Cancer Research Annual Meeting In Chicago April 25-30, 2025

Guidance

Senti Bio Sciences Q4 EPS ($0.67) Up From ($4.19) YoY.

Press Releases

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

Legal

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Senti Biosciences, Inc. - SNTI

Senti Biosciences Announces New Employment Inducement Grants

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

Comments

Senti Biosciences

Senti Biosciences (SNTI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO